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The cullin-RING ubiquitin ligase, CRL1SKP2, directing the degradation of the tumor suppressor p27, is a well
validated drug target in a wide variety of human cancers. In this issue of Chemistry & Biology, Wu and
colleagues describe first-in-class small molecule inhibitors of CRL1SKP2-mediated degradation of p27.Protein kinases are prime targets in tar-
geted cancer therapy. By sheer numbers,
E3 ubiquitin ligases—enzymes that facili-
tate the final step of ubiquitin attachment
to protein substrates, thus dispatching
them to the proteasome for degrada-
tion—would seem to constitute an equally
exciting target space. However, despite
increasing understanding of the bio-
chemistry and physiology of these
enzymes, specific targeting of E3s with
small molecules has remained frustrat-
ingly difficult. The main reason for this
may be that, unlike kinases, E3s are not
known to possess catalytic pockets
that can be readily targeted by a small
molecule inhibitor. Thus, development
options are largely confined to disrupting
protein-protein interactions, a proposition
notoriously destined for failure, or so we
thought.
Arguably, few E3s are better validated
as potential cancer drug targets than
CRL1SKP2 (also known as SCFSKP2).
CRL1SKP2 is a member of the large family
of cullin-RING ligases, multisubunit E3s
consisting of a core complex of CUL1
and the RING domain protein RBX1 to
which heterodimers of SKP1 and F-box
containing substrate receptors are re-
cruited (Figure 1). One of these substrate
receptors is SKP2, which, together with
another small protein, CKS1, specifically
recruits the cyclin-dependent kinase
(CDK) inhibitor and tumor suppressor
p27KIP1 to mediate its polyubiquitylation
and proteasomal degradation. Notably,
SKP2 and CKS1 are frequently overex-
pressed in cancers, leading to ectopic
p27 degradation, unrestrained prolifera-
tion, and poor patient prognosis (Chu
et al., 2008). For example, transgenic
expression of SKP2 in themouse prostate
causes low-grade prostate carcinomasthat coincide with p27 downregulation.
Conversely, silencing of SKP2 expression
inhibits tumor growth in various model
systems. SKP2/ knockout mice are
small and display general organ hypo-
plasia, phenotypes that are fully rescued
by simultaneous deletion of p27. These
findings validated CRL1SKP2 as a formi-
dable cancer drug target (Cardozo and
Pagano, 2007). Considering that virtually
all normal differentiated cells express
high levels of p27, compounds interfering
with p27 degradation have a high poten-
tial for tumor specificity, thus promising
a favorable safety profile.
Based on this rationale, several strate-
gies have been developed to pharmaco-
logically antagonize p27 degradation in
cancer cells. These strategies vary widely
in their specificity for p27 and, hence, in
their predicted tolerability (Figure 1). On
one end of the spectrum are proteasome
inhibitors such as bortezomib. While
highly effective against multiple myeloma,
dose limiting toxicities prevent the appli-
cation of bortezomib in solid tumors. Like-
wise, the proteasome inhibitor Argyrin A
has shown remarkable activity in driving
p27-dependent cancer cell apoptosis in
mouse models (Nickeleit et al., 2008).
Other agents broadly impacting on E3
activity include inhibitors of E1 ubiquitin
activating enzyme (Brownell et al., 2010).
Higher specificity is afforded by CC0651,
a recently discovered allosteric inhibitor
of the E2 CDC34, which ubiquitylates
p27 in concert with CRL1SKP2 (Ceccarelli
et al., 2011). However, as expected, this
compound also interferes with the degra-
dation of other CDC34 substrates such
as cyclin E. Similarly, MLN4924, a drug
that inhibits attachment of the activating
NEDD8 modification to cullins leads to
accumulation of p27 but also many otherChemistry & Biology 19, December 21, 2012 ªCRL substrates (Soucy et al., 2009).
Yet, a higher level of p27 specificity is
afforded by compounds, which disrupt
the interaction of SKP1 with SKP2 (Chen
et al., 2008), downregulate SKP2 ex-
pression (Rico-Bautista et al., 2010), or
inhibit CDKs to prevent phosphorylation-
dependent binding of p27 to SKP2-
CKS1. Again, in all three instances,
additional substrates of SKP2 or CDKs
would be expected to be affected by
these regimens.
As far as specificity goes, Wu et al.
(2012), in this issue of Chemistry &
Biology, have unearthed what appears
to be no less than the Holy Grail of the
pharmacologic targeting of CRL1SKP2:
compounds that prevent the ubiquityla-
tion and degradation of only a single
class of substrates, p27 and the related
CDK inhibitor p21 (and perhaps p57).
The feat was achieved by focusing
in silico screening on a phospho-p27
binding pocket uniquely formed by a
complex between SKP2 and CKS1. As
predicted by docking, the resultant
compounds C1, 2, 16, and 20 (collectively
dubbed ‘‘SKPins’’ for the purpose of
this article) assume similar poses in
their binding pocket, thereby disrupting
critical interactions between phospho-
p27 and SKP2-CKS1. SKPins show
impressive selectivity for CRL1SKP2-
mediated p27 degradation, neither im-
pairing the activity of E1, E2, or other
E3 enzymes (CRL1b-TRCP, MDM2) nor
causing stabilization of other SKP2
substrates. The latter finding can be
rationalized by the strict dependency of
the mechanism of action of SKPins
on CKS1. Finally, the authors rule out
possible inhibitory effects of SKPins on
p27 phosphorylation. SKPin-mediated
p27 stabilization is subsequently shown2012 Elsevier Ltd All rights reserved 1497
Figure 1. Strategies for Targeting p27 Degradation with Small Molecules
Small molecules targeting various steps in the p27 degradation pathway are indicated. The specificity of
the inhibitors for p27 increases from right to left with SKPins, discovered in the work by Wu et al. (2012),
showing the highest specificity, directly disrupting the binding of phosphorylated p27 to the CRL1
substrate receptor unit formed by SKP2 and CKS1. p27 specificity is presumed to be inversely correlated
with toxicity of the inhibitors. The antitumor efficacy in humans is unknown for most of the compounds
listed with the exception of proteasome and neddylation inhibitors. Conceptually, the high specificity
of SKPins for inhibiting p27 degradation appears to have a higher likelihood for redundancies that limit
efficacy than less specific agents such as proteasome inhibitors. SMIP004, etc. refers to a group of
compounds that downregulate SKP2 mRNA through complex mechanisms (Rico-Bautista et al., 2010).
For completeness, SMER3 references a compound that disrupts the interaction of SKP1 with the yeast
CRL1 substrate receptor Met30 (Aghajan et al., 2010).
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cancer cells lines in a p27 and SKP2-
dependent manner.
Although SKPins provide striking proof-
of-principle for the feasibility of targeting
of CRL1-substrate interactions with small
molecules, thinking ahead to a possible
clinical application, several questions
remain. For one, the in vitro cytotoxic
activity of SKPins identified in melanoma
and breast cancer cell lines was not
referenced to ‘‘normal,’’ i.e., untrans-
formed cells, thus rendering the cancer
cell selectivity of the compounds uncer-
tain. It also remains to be seen if the
current hit series will be bioactive in
humans or if suitable analogs can be
developed. Likewise, the safety profile of
SKPins is currently unknown because
possible off-target effects have not been
ruled out. The conceptual question of
whether or not the upregulation of p27
in cancer cells bears risks connected
with the cell migration promoting activity1498 Chemistry & Biology 19, December 21,identified for cytoplasmically localized
p27 is also unanswered. Finally, whereas
SKPins were shown to exert their growth
inhibitory function through SKP2 in the
short run, it remains possible that parallel
degradation pathways mediated by other
p27-directed E3s such as PIRH2 and
KPC will compensate for the loss of
CRL1SKP2 activity in the long run. Thus,
while SKPins, unlike proteasome or
NEDD8 E1 inhibitors, appear exquisitely
specific for CRL1SKP2; their very speci-
ficity may also compromise their long-
term clinical efficacy due to the rapid
enlistment of redundant pathways. As
such, the true potential of SKPins (or
more advanced analogs derived from
them) may lie in their application as
chemosensitizers to augment other cyto-
static treatments.
Regardless, the current study highlights
the power of structure-based approaches
for chemical targeting of E3-substrate
interactions. The same in silico strategy2012 ª2012 Elsevier Ltd All rights reservedwas effective in another case, identifying
nutlins as inhibitors of the interaction of
MDM2 with p53 (Vassilev et al., 2004).
With these two successes, structure-
based approaches are emerging as
promising avenues toward identifying
pharmacophores able to revive other
tumor suppressors that are frequently
depleted by ectopic degradation, PTEN
being a prominent one.
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